|
1
|
Kamada T, Tsujii H, Blakely EA, Debus J,
De Neve W, Durante M, Jäkel O, Mayer R, Orecchia R, Pötter R, et
al: Carbon ion radiotherapy in Japan: An assessment of 20 years of
clinical experience. Lancet Oncol. 16:e93–e100. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yasueda A, Urushima H and Ito T: Efficacy
and interaction of antioxidant supplements as adjuvant therapy in
cancer treatment: A systematic review. ntegr. Integr Cancer Ther.
15:17–39. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Skvortsova I, Debbage P, Kumar V and
Skvortsov S: Radiation resistance: Cancer stem cells (CSCs) and
their enigmatic pro-survival signaling. Semin Cancer Biol.
35:39–44. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Baek SJ, Ishii H, Tamari K, Hayashi K,
Nishida N, Konno M, Kawamoto K, Koseki J, Fukusumi T, Hasegawa S,
et al: Cancer stem cells: The potential of carbon ion beam
radiation and new radiosensitizers (Review). Oncol Rep.
34:2233–2237. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kunkel TA: DNA replication fidelity. J
Biol Chem. 279:16895–16898. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Haraguchi N, Ishii H, Mimori K, Tanaka F,
Ohkuma M, Kim HM, Akita H, Takiuchi D, Hatano H, Nagano H, et al:
CD13 is a therapeutic target in human liver cancer stem cells. J
Clin Invest. 120:3326–3339. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ishimoto T, Nagano O, Yae T, Tamada M,
Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, et al:
CD44 variant regulates redox status in cancer cells by stabilizing
the xCT subunit of system xc(−) and thereby promotes Tumor Growth.
Cancer Cell. 19:387–400. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wada T, Ishimoto T, Seishima R,
Tsuchihashi K, Yoshikawa M, Oshima H, Oshima M, Masuko T, Wright
NA, Furuhashi S, et al: Functional role of CD44v-xCT system in the
development of spasmolytic polypeptide-expressing metaplasia.
Cancer Sci. 104:1323–1329. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peters CJ: Therapeutic potential of
TAS-102 in the treatment of gastrointestinal malignancies. Ther Adv
Med Oncol. 7:340–356. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Uhl M, Herfarth K and Debus J: Comparing
the use of protons and carbon ions for treatment. Cancer J.
20:433–439. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cui X, Oonishi K, Tsujii H, Yasuda T,
Matsumoto Y, Furusawa Y, Akashi M, Kamada T and Okayasu R: Effects
of carbon ion beam on putative colon cancer stem cells and its
comparison with X-rays. Cancer Res. 71:3676–3687. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ishikawa H, Tsuji H, Kamada T, Akakura K,
Suzuki H, Shimazaki J and Tsujii H: Working Group for Genitourinary
Tumors: Carbon-ion radiation therapy for prostate cancer. Int J
Urol. 19:296–305. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tsujii H and Kamada T: A review of update
clinical results of carbon ion radiotherapy. Jpn J Clin Oncol.
42:670–685. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nakano T, Suzuki Y, Ohno T, Kato S, Suzuki
M, Morita S, Sato S, Oka K and Tsujii H: Carbon beam therapy
overcomes the radiation resistance of uterine cervical cancer
originating from hypoxia. Clin Cancer Res. 12:2185–2190. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mizoe JE, Hasegawa A, Jingu K, Takagi R,
Bessyo H, Morikawa T, Tonoki M, Tsuji H, Kamada T, Tsujii H, et al:
Results of carbon ion radiotherapy for head and neck cancer.
Radiother Oncol. 103:32–37. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jingu K, Tsujii H, Mizoe JE, Hasegawa A,
Bessho H, Takagi R, Morikawa T, Tonogi M, Tsuji H, Kamada T and
Yamada S: Organizing Committee for the Working Group for
Head-and-Neck Cancer: Carbon ion radiation therapy improves the
prognosis of unresectable adult bone and soft-tissue sarcoma of the
head and neck. Int J Radiat Oncol Biol Phys. 82:2125–2131. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sato K, Imai T, Okayasu R and Shimokawa T:
Heterochromatin domain number correlates with x-ray and carbon-ion
radiation resistance in cancer cells. Radiat Res. 182:408–419.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chandel NS: Evolution of Mitochondria as
Signaling Organelles. Cell Metab. 22:204–206. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Temmink OH, Emura T, de Bruin M, Fukushima
M and Peters GJ: Therapeutic potential of the dual-targeted TAS-102
formulation in the treatment of gastrointestinal malignancies.
Cancer Sci. 98:779–789. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mayer RJ, Van Cutsem E, Falcone A, Yoshino
T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero
J, Komatsu Y, et al: Randomized trial of TAS-102 for refractory
metastatic colorectal cancer. N Engl J Med. 372:1909–1919. 2015.
View Article : Google Scholar : PubMed/NCBI
|
